AllRock Bio’s drug is a small molecule pan-ROCK inhibitor ready for Phase 2 testing in pulmonary arterial hypertension and pulmonary hypertension with interstitial lung disease. The startup is led by the management team that steered CinCor Pharma to a $1.3 billion acquisition by AstraZeneca.
The post With Drug Picked Up From Sanofi, Startup AllRock Takes Aim at Two Severe Lung Diseases appeared first on MedCity News.
